Related Experiment Video

Updated: May 10, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Revisited role of microparticles in arterial and venous thrombosis

R Lacroix1, C Dubois, A S Leroyer

  • 1VRCM, UMR_S1076, UFR de Pharmacie, Aix Marseille Université, INSERM, Marseille, France.

Journal of Thrombosis and Haemostasis : JTH
|July 2, 2013
PubMed

Insights

Microparticles (MPs), small vesicles released by cells, are increasingly linked to thrombosis. This review explores their complex role in blood clotting and potential as diagnostic biomarkers.

Area of Science:

  • Hematology
  • Cell Biology
  • Biochemistry

Background:

  • Microparticles (MPs) are submicronic vesicles released during cell activation or apoptosis.
  • MPs carry cell-specific molecules and influence biological functions.
  • Elevated circulating MPs are observed in thrombosis-associated disorders.

Purpose of the Study:

  • To present a new perspective on MPs as complex regulators of coagulation and fibrinolysis.
  • To review the role of MPs in venous and arterial thrombosis.
  • To discuss the implications of this new vision for MPs as biomarkers in thrombotic diseases.

Main Methods:

  • Literature review of studies on MPs and thrombosis.
  • Analysis of MP expression of coagulation activators, inhibitors, and fibrinolytic properties.
  • Evaluation of the predictive value of MPs in thrombotic diseases.

Main Results:

  • MPs exhibit dual roles, expressing both pro-coagulant and anti-coagulant factors.
  • MPs possess fibrinolytic properties, contributing to clot regulation.
  • Limited studies show predictive value, with unclear reasons for inconsistency.

Conclusions:

  • MPs are complex, ambivalent structures crucial for balancing coagulation and fibrinolysis.
  • The precise role of MPs in thrombosis requires further investigation.
  • Standardization and a comprehensive understanding are needed to establish MPs as reliable biomarkers for thrombotic diseases.
Keywords:
biomarkercell-derived microparticlescoagulationfibrinolysisriskthrombosis

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...